medigraphic.com
ISSN 1405-8871 (Print)

2021, Number 1

<< Back Next >>

Aten Fam 2021; 28 (1)

Association Between Treatments in Breast Cancer Patients with Clinical and Molecular Classification

Vázquez MFA, Gómez GA, Gutiérrez CS

Language: Spanish
References: 17
Page: 21-25
PDF size: 150.47 Kb.


ABSTRACT

Objective: to determine the types of treatments in patients with breast cancer according to a clinical and molecular classification, in a Family Medicine Unit. Methods: a cross sectional study based on the review of 88 files that met the requirements of the selection criteria. A data collection format was designed to know the year breast cancer was diagnosed, type of treatment, TNM classification, and molecular profile. The results are shown in frequencies, mean and standard deviation. Results: the average age was 54.5 (±11.4 years), most of the detected cancer types were luminal B with 52% of cases, which were mainly associated to adjuvant chemotherapy (P=0.0001), while triple negative ones were associated to radical surgery (P=0.002). On the other hand, the patients who required the most neoadjuvant, adjuvant and surgical treatment were in stage I at the time of diagnosis, P=0.004, P=0.028 and P=0.007, respectively. Conclusions: correlating treatment types with molecular and TNM classification, it was observed that a significant fraction of patients with luminal B breast cancer required adjuvant chemotherapy and radical surgery, while most triple negative patients required radical surgery.


REFERENCES

  1. Kumar V, Abbas AK, Fausto N, Aster JC. Patología estructural y funcional. 2010. Elsevier. 1065- 1095.

  2. Gómez Dantés H, Lamadrid Figueroa H, Cahuana Hurtado L, et al. The Burden of Cancer in Mexico, 1990-2013. Salud Pub Mex. 2016;58:118-131

  3. Golditz G, Baer H, Tamimi R. Cancer Epidemiology and Prevention, 3rd ed, New York: Oxford Press, 2006.

  4. Sánchez Ceja SG, Reyes Maldonado ME, Vázquez Manríquez ME, López Luna JJ, Belmont A y Gutiérrez Castellanos S. Differential expression of STAT5 and Bcl-xL, and high expression of Neu and STAT3 in non-smal-cell lung carcinoma. Lung Cancer. 2006;54:163-168.

  5. Tavassoll FA, Devilee P. Word Healt Organization. Classification of Tumours. Pathology and genetics of tumours of the breast and female genital organs. International Agency for Research on Cancer, Press: Lyon 2003

  6. Harris L, Fritsche H, Menuel R, Norton L, Ravdin P, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25(33):5287-5312.

  7. Consenso Mexicano sobre diagnóstico y tratamiento del cáncer mamario [Internet]. [Citado 2020 Nov 04]. Disponible en: http:// consensocancermamario.com/documentos/FOLLETO_ CONSENSO_DE_CANCER_DE_ MAMA_8aRev2019a.PDF

  8. Russnes HG, Lingjaerde OC, Borresen Dale AL, Caldas C. Breast Cancer molecular stratification from intrinsic subtypes to integrative clusters. American Journal of Pathology. 2017;187(10):2152-2162.

  9. Guía de práctica clínica, prevención y diagnóstico oportuno de cáncer de mama en el primer nivel de atención. Evidencias y recomendaciones. Centro Nacional de Excelencia Tecnológica en Salud (CENETEC). 2014.

  10. Rodríguez Cuevas S, Macías Suárez G, Franceschi D. Breast carcinoma presents a decade earlier in Mexican women than in women in the United States or European countries. Cancer. 2011;91(4):863-868.

  11. Maffuz Aziz A, Labastida Almendaro S, Espejo Fonseca A, et al. Clinical and pathological features of breast cancer in a population of Mexico. Cir Cir. 2017;85(3)201-207.

  12. Franzoi MA, Rosa DD, Zaffaroni F, Werutsky G, Simon S, Bines J, et al. Advanced stage at diagnosis and worse clinocpathologic features in Young women with breast cáncer in Brazil: a subanalysis of the AMAZONA III study. J Glob Oncol. 2019;5:1-10.

  13. Lester SC, Bose S, Chen YY, et al. Template for reporting results of biomarker testing of specimens from patients with carcinoma of the breast. College of American Pathologists. 2014;15:1-37.

  14. Godoy Ortiz A, Sanchez Muñoz A, Chica Parrado MR, et al. Deciphering HER2 Breast Cancer Disease: Biological and Clinical Implications. Front Oncol. 2019;9:1124.

  15. Brinton LA, Sherman ME, Carreon JD, Anderson WF. Recent trends in breast cancer among younger women in the United States. J Natl Cancer Inst. 2008;100(22):1643-1648.

  16. Ades F, Zardavas D, Bozovic Spasojevic I, et al. Luminal B breast cancer: molecular characterization, clinical management, and future perspectives. J Clin Oncol. 2014;32(25):2794-2803.

  17. Boér K. Adjuvant chemotherapy of early stage breast cancer. Orv Hetil. 2010;151(9):344-353.




2020     |     www.medigraphic.com